×
About 9,543 results

CDC: The US 2021-2022 Influenza Season Was Mild and Driven by A(H3N2), a Strain Included in 2022-2023 Vaccines
https://www.medscape.com/viewarticle/978795

Aug 8th, 2022 - During the 2021-2022 flu season, influenza activity in the United States was lower than pre-pandemic levels despite increased reporting and testing, possibly owing to COVID-19 precautions, according to a new report from the US Centers for Disease Control and Prevention (CDC). For the 2022-2023 season, CDC has updated recommendations for the annual vaccine to include a closer antigenic match to ...

Mysterious Cases of Illness With an Unusual Cause
https://www.medscape.com/viewarticle/978807

Aug 8th, 2022 - In 2021, in US states far removed from one another, numerous cases of melioidosis (Whitmore's disease) sprung up, some with a fatal outcome. What is the common factor linking all of those affected? So begins the search for evidence. No Relations or Common Journeys Between March and July 2021, cases of the bacterial infectious disease sprung up in Georgia, Kansas, Minnesota, and Texas, with the ...

tDCS for Post COVID-19 Fatigue
https://clinicaltrials.gov/ct2/show/NCT04876417

Aug 5th, 2022 - For survivors of severe COVID-19, overcoming the virus is just the beginning of an uncharted recovery path. As the number of confirmed COVID-19 cases exceeds 27 million globally and 6 million in the US, the number of patients who experience persistent symptoms during recovery is rapidly growing. In COVID-19 patients, common acute symptoms include cough, fever, dyspnea, musculoskeletal symptoms ...

Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test
https://clinicaltrials.gov/ct2/show/NCT04808921

Aug 5th, 2022 - The clinical performance of the SARS-CoV-2 Antigen Rapid test was evaluated in a prospective clinical study conducted at a single (1) CLIA waiver investigational site in Miami, Florida, U.S. Consenting patients of any age, gender, or race/ethnicity who presented at the test site with COVID-19 like symptoms during the 2021 COVID-19 season were sequentially enrolled and tested. Five (5) minimally...

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
https://clinicaltrials.gov/ct2/show/NCT04401436

Aug 5th, 2022 - Coronavirus disease 2019 (COVID-19) is an acute respiratory syndrome caused by the novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The emergence of SARS-CoV-2 has led to a pandemic with a wide range of manifestations. One of the hallmarks of severe illness is the presence of elevated levels of inflammatory biomarkers, coagulopathy, and lymphopenia. Lymphopenia is...

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
https://clinicaltrials.gov/ct2/show/NCT04611802

Aug 5th, 2022 - This is a Phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants ≥ 18 years of age (Adult Main Study) and adolescent participants 12 to <18 years (Pediatric Expansion). Additionally, a Booster Amendment will allow for the evaluation of a booster dose of SARS-CoV-2 rS with...

Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
https://clinicaltrials.gov/ct2/show/NCT04569266

Aug 5th, 2022 - During these episodes of respiratory insufficiency, the management is based on ventilatory replacement by generally invasive mechanical ventilation. This allows correction of hematosis disorders but can lead to complications either directly (respiratory infections) or indirectly (neuromuscular complications and/or complications related to prolonged bed rest requiring prolonged re-education). Al...

Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04988217

Aug 5th, 2022 - The IN2COVID Study is a 2-staged phase I/II double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of AP-003 (Interferon α2b) when administered via inhalation twice daily for 10 days. Participants will have a final visit at Day 11. A lead-in phase 1 substudy will be performed with at least 18 healthy adult male subjects to assess safety and tolerability of inhale...

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19
https://clinicaltrials.gov/ct2/show/NCT05044780

Aug 5th, 2022 - Background The Coronavirus Disease 19 (COVID19) pandemic has challenged healthcare systems worldwide. Massive testing, contact tracing and social distancing proved to be the most effective tools to fight the pandemic prior to the development of vaccines. Despite the effort to develop rapid diagnostic testing, we still don t have an available large population screening modality. Analysis of swea...

Impact of COVID19 on Asthma
https://clinicaltrials.gov/ct2/show/NCT05064501

Aug 5th, 2022 - The COVID19 pandemic is having an immeasurable impact on the economy and on morbidity and mortality. Knowledge and scientific evidence about this disease is advancing rapidly, but it is not yet known whether asthmatic patients suffering from COVID19 have an exacerbation of asthma, or whether this viral infection has an impact on control and lung function in the short to medium term. The aim of ...

Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
https://clinicaltrials.gov/ct2/show/NCT05484700

Aug 5th, 2022 - This retrospective cohort study compared immunogenicity post COVID-19 between individuals (aged 18-65 years and had confirmed SARS-CoV-2 infection from January to May 2022 ) with residual Long COVID-19 symptoms (LC) and ones with full recovery (Full) related to pathophysiology, immunology and clinical consequence.

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study
https://clinicaltrials.gov/ct2/show/NCT05484882

Aug 5th, 2022 - STUDY DESCRIPTION The objective is to conduct a prospective natural history study of Coronavirus disease 2019 (COVID-19) among a community-based cohort of African Americans enrolled in GENE-FORECAST for whom we have comprehensive psychosocial, clinical, and genetic data collected at baseline. Participants will be invited to take part in a 20-minute computer-assisted telephone interview (CATI) o...

A Real-world Retrospective Study of Disease Outcomes in Non-severe COVID-19 Patient
https://clinicaltrials.gov/ct2/show/NCT05489874

Aug 5th, 2022 - This is a retrospective, observational, real-world study to review outcomes of Mild to Moderate COVID-19 patients admitted to Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine (hereinafter referred to as Ruijin Hospital) from March to June 2022. These patients should be with risk factors for progression to severe disease (including death) and without definitive anti-...

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
https://clinicaltrials.gov/ct2/show/NCT05481216

Aug 5th, 2022 - HIV CoCo is a European multi-centre, multi-country, retrospective, observational case-control study that will aim to describe clinical outcomes and identify risk factors for People Living With HIV (PLWHIV) who are co-infected with the SARS-CoV-2 coronavirus. The study will address two central questions: Is there a particular risk for COVID-19 in PLWHIV as compared to HIV seronegative control CO...

ImmuneSense™ COVID-19 Cross-Reactivity Study
https://clinicaltrials.gov/ct2/show/NCT05112874

Aug 5th, 2022 - Prospective ascertainment of a minimum of 10 individuals exhibiting symptoms of viral upper respiratory tract infections, between the ages of 18-89 residing within the United States and being tested for SARS-CoV-2 infection during the 2021-2022 cold and flu season (~Nov. 2021 - May 2022). Participants will complete an electronic screening questionnaire to determine eligibility, be consented, an...

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
https://clinicaltrials.gov/ct2/show/NCT05364242

Aug 5th, 2022 - This is a multicentric, open-label, phase 2/3 study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination standard dose in adults aged ≥18 to ≤50 years or double dose in volunteers aged >50 years. Volunteers who are either generally healthy or are with a stable medical condition will be enrolled. In total approximately 275 participants are planned to be enr...

Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04582344

Aug 4th, 2022 - This study is a randomized, double-blinded, multi-center, placebo-controlled phase III clinical trial in adults aged 18~59 years. The purpose of this study is to evaluate the efficacy, safety and immunogenicity of the experimental SARS-CoV-2 inactivated vaccine. The experimental vaccine and placebo were both manufactured by Sinovac Research & Development Co., Ltd. A total of 13.000 subjects wil...

DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04836780

Aug 4th, 2022 - Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress syndrome (ARDS), severe hypoxic respiratory failure and, death. It has been reported that the mechanism of COVID-19 is related to cytokine storms and subsequent immunogenic damage, especially lung damage. Dexamethasone, with immunomodulatory properties, decrease mortality in critically ill patients with COVID-19. However...

Novel Experimental COVID-19 Therapies Affecting Host Response
https://clinicaltrials.gov/ct2/show/NCT04924660

Aug 4th, 2022 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. The clinical spectrum of COVID-19 infection is broad, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and death. Between 13 and 40% of patients become hospitalized, up...

Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff
https://clinicaltrials.gov/ct2/show/NCT04799808

Aug 4th, 2022 - Formation of two separate cohorts of approximately 1000 study subjects each from the three categories (dialysis patients, solid organ transplant recipients and medical staff) of participants vaccinated using either Biontech or Moderna vaccine (Biontech cohort and Moderna cohort, approximately 2000 subjects total). Study time points: Before administration of the 1st SARS-CoV-2 vaccine dose, befo...